Who are CKD-843 dose#2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metformin and Pioglitazone, PUFAs, CKD-314+SOC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ckd-843-dose-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CKD-843 dose#2 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CKD-843 dose#2 (CKD-843 dose#2) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PPAR-gamma agonist. Area: Metabolic/Endocrinology.

phase 3 PPAR-gamma agonist PPAR-gamma Metabolic/Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

CKD-843 dose#2 (CKD-843 dose#2) — Chong Kun Dang Pharmaceutical. CKD-843 is a selective PPAR-gamma agonist that enhances insulin sensitivity and reduces inflammation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CKD-843 dose#2 TARGET	CKD-843 dose#2	Chong Kun Dang Pharmaceutical	phase 3	PPAR-gamma agonist	PPAR-gamma
Metformin and Pioglitazone	Metformin and Pioglitazone	King Edward Medical University	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	Metformin: AMP-activated protein kinase (AMPK) pathway; Pioglitazone: PPAR-gamma
PUFAs	PUFAs	Federal University of São Paulo	phase 3	Fatty acid	PPAR-alpha, PPAR-gamma
CKD-314+SOC	CKD-314+SOC	Chong Kun Dang Pharmaceutical	phase 3	PPAR-gamma agonist	PPAR-γ (Peroxisome proliferator-activated receptor gamma)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PPAR-gamma agonist class)

Chong Kun Dang Pharmaceutical · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CKD-843 dose#2 — Competitive Intelligence Brief. https://druglandscape.com/ci/ckd-843-dose-2. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing